MA55614A - Formes cristallines d'inhibiteur de pyridazinone trpc - Google Patents
Formes cristallines d'inhibiteur de pyridazinone trpcInfo
- Publication number
- MA55614A MA55614A MA055614A MA55614A MA55614A MA 55614 A MA55614 A MA 55614A MA 055614 A MA055614 A MA 055614A MA 55614 A MA55614 A MA 55614A MA 55614 A MA55614 A MA 55614A
- Authority
- MA
- Morocco
- Prior art keywords
- trpc
- pyridazinone
- inhibitor
- crystalline forms
- crystalline
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 102000027549 TRPC Human genes 0.000 title 1
- 108060008648 TRPC Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/081985 WO2020206623A1 (fr) | 2019-04-10 | 2019-04-10 | Formes cristallines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55614A true MA55614A (fr) | 2022-02-16 |
Family
ID=70482847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055614A MA55614A (fr) | 2019-04-10 | 2020-04-10 | Formes cristallines d'inhibiteur de pyridazinone trpc |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220177455A1 (fr) |
| EP (1) | EP3953352A1 (fr) |
| JP (2) | JP7738482B2 (fr) |
| CN (2) | CN119264134A (fr) |
| AU (2) | AU2020272030C1 (fr) |
| BR (1) | BR112021018221A2 (fr) |
| CA (1) | CA3136652A1 (fr) |
| MA (1) | MA55614A (fr) |
| MX (2) | MX2021012313A (fr) |
| WO (2) | WO2020206623A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018334290A1 (en) | 2017-09-18 | 2020-04-02 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| IL281438B2 (en) * | 2018-09-18 | 2023-12-01 | Goldfinch Bio Inc | Pyridazinones and methods of use thereof |
| MX2021012310A (es) * | 2019-04-11 | 2021-11-12 | Goldfinch Bio Inc | Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona. |
| MX2022004049A (es) * | 2019-10-04 | 2022-07-11 | Goldfinch Bio Inc | Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica. |
| IL299623A (en) * | 2020-07-03 | 2023-03-01 | Wuhan Ll Science & Technology Development Co Ltd | Heterocyclic compound and its use |
| CN117940417A (zh) * | 2021-09-10 | 2024-04-26 | 南京明德新药研发有限公司 | 卤素取代的哒嗪酮类化合物及其应用 |
| CN118678957A (zh) * | 2022-01-27 | 2024-09-20 | 武汉朗来科技发展有限公司 | 一种杂环化合物的应用 |
| WO2024027752A1 (fr) * | 2022-08-05 | 2024-02-08 | 武汉朗来科技发展有限公司 | Composition pharmaceutique comprenant un composé hétérocyclique, procédé de préparation associé et utilisation correspondante |
| WO2025250920A1 (fr) | 2024-05-31 | 2025-12-04 | Gfb (Abc), Llc | Composés de pyridazinone phosphate, compositions pharmaceutiques et leurs utilisations médicales |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP310798A0 (en) * | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
| US8633233B2 (en) * | 2008-08-06 | 2014-01-21 | Hydra Biosciences, Inc. | Methods and compositions for treating anxiety |
| WO2016023830A1 (fr) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
| AU2018334290A1 (en) * | 2017-09-18 | 2020-04-02 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| IL281438B2 (en) | 2018-09-18 | 2023-12-01 | Goldfinch Bio Inc | Pyridazinones and methods of use thereof |
-
2019
- 2019-04-10 WO PCT/CN2019/081985 patent/WO2020206623A1/fr not_active Ceased
-
2020
- 2020-04-10 MA MA055614A patent/MA55614A/fr unknown
- 2020-04-10 WO PCT/US2020/027689 patent/WO2020210639A1/fr not_active Ceased
- 2020-04-10 CA CA3136652A patent/CA3136652A1/fr active Pending
- 2020-04-10 JP JP2021555545A patent/JP7738482B2/ja active Active
- 2020-04-10 BR BR112021018221A patent/BR112021018221A2/pt unknown
- 2020-04-10 MX MX2021012313A patent/MX2021012313A/es unknown
- 2020-04-10 AU AU2020272030A patent/AU2020272030C1/en active Active
- 2020-04-10 EP EP20723672.0A patent/EP3953352A1/fr active Pending
- 2020-04-10 CN CN202411019840.2A patent/CN119264134A/zh active Pending
- 2020-04-10 CN CN202080042302.9A patent/CN114502552B/zh active Active
- 2020-04-10 US US17/603,249 patent/US20220177455A1/en active Pending
-
2021
- 2021-10-07 MX MX2025006384A patent/MX2025006384A/es unknown
-
2025
- 2025-09-01 JP JP2025144862A patent/JP2026004294A/ja active Pending
-
2026
- 2026-02-11 AU AU2026201003A patent/AU2026201003A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114502552B (zh) | 2024-08-16 |
| WO2020206623A1 (fr) | 2020-10-15 |
| AU2020272030B2 (en) | 2025-11-13 |
| AU2020272030A1 (en) | 2021-11-11 |
| WO2020210639A1 (fr) | 2020-10-15 |
| MX2025006384A (es) | 2025-07-01 |
| MX2021012313A (es) | 2021-11-17 |
| US20220177455A1 (en) | 2022-06-09 |
| JP2022525759A (ja) | 2022-05-19 |
| BR112021018221A2 (pt) | 2022-01-18 |
| AU2026201003A1 (en) | 2026-03-05 |
| CN119264134A (zh) | 2025-01-07 |
| EP3953352A1 (fr) | 2022-02-16 |
| JP2026004294A (ja) | 2026-01-14 |
| CA3136652A1 (fr) | 2020-10-15 |
| JP7738482B2 (ja) | 2025-09-12 |
| AU2020272030C1 (en) | 2026-05-07 |
| CN114502552A (zh) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3870178A4 (fr) | Formes cristallines d'inhibiteurs de mnk | |
| EP3924352A4 (fr) | Formes cristallines d'un inhibiteur rsk | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| DK4045039T3 (da) | Hæmning af human integrin-alfa4beta7 | |
| EP3947361A4 (fr) | Sel et forme cristalline d'un inhibiteur de fak | |
| EP3870181A4 (fr) | Formes cristallines d'un inhibiteur d'alk2 | |
| IL286218A (en) | Solid state forms of ripretinib | |
| DK4058453T3 (da) | Forbedret syntese af kras g12c-inhibitorforbindelse | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3619208C0 (fr) | Formes cristallines d'un composé inhibiteur de jak | |
| EP4337203A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3786157A4 (fr) | Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
| EP3782987A4 (fr) | Composé de benzo-pyrazole tenant lieu d'inhibiteur de la rho-kinase | |
| MA54689A (fr) | Formes cristallines de 1-(1,2-diméthylpropyl)-n-éthyl-5-méthyl-n-pyridazin-4-yl-pyrazole-4-carboxamide | |
| EP3866780C0 (fr) | Dérivés de flavagline pour inhiber l'activation de l'oncogène kras | |
| EP3897660A4 (fr) | Nouvelles formes cristallines d'un composé de nrtti | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| EP3870179A4 (fr) | Inhibition d'usp7 | |
| EP3644993A4 (fr) | Formes amorphes et cristallines d'inhibiteurs de l'ido | |
| EP3730483A4 (fr) | Classe d'inhibiteurs de kinase dérivés de pyrimidine | |
| EP3954683A4 (fr) | Promédicament d'inhibiteur de caspase | |
| EP3996707A4 (fr) | Formes cristallines d'inhibiteurs de la kallicréine plasmatique |